Skip to the shortlist
Peptide ClarityGuide
Question

Does Ozempic slow down digestion? Yes, by design

What the label says about semaglutide and your stomach, how big the slowdown is, whether it fades, and which symptoms need a call.

Mara Whitford

Heads up: Peptide Clarity Guide works with partners, and a few buttons below pay us if you join (you pay the same). Here partners are listed first; that never changes a word we write about anyone. How we earn.

The short answer

Yes. Ozempic's FDA label says semaglutide delays early stomach emptying after meals, which is part of how it lowers blood sugar and appetite. In a small scan study, 37% of a solid meal was still in the stomach after four hours on semaglutide, versus none on placebo. Severe or lasting symptoms need a prescriber's attention.

Key takeaways

  • Delayed early stomach emptying is a labeled effect of semaglutide, the drug in Ozempic and Wegovy.
  • In a small scan study, 37% of a solid meal was still in the stomach after 4 hours, versus none on placebo.
  • The label lists ileus, intestinal obstruction and severe constipation from postmarketing reports.
  • Ozempic isn't recommended for people with severe gastroparesis, and it carries a warning about aspiration under anesthesia.
  • Nausea, vomiting, diarrhea, stomach pain and constipation are its most common side effects.

Here's the short version. Semaglutide slows how fast food leaves your stomach. That isn't a glitch. It's one of the ways the drug keeps blood sugar steadier and helps you feel full. Fullness, nausea or constipation can occur. Severe or persistent symptoms need medical review.

How Ozempic slows digestion

Semaglutide delays early stomach emptying after meals. The label says it "causes a delay of early postprandial gastric emptying, thereby reducing the rate at which glucose appears in the circulation" [1]. In plain words: food, and the sugar in it, reaches your bloodstream more slowly.

A slower stomach also means you stay full longer, which is part of why people eat less. Effects on appetite signals in the brain play a role too. That side of the story is in what Ozempic does to your brain.

What the Ozempic label says about digestion (current DailyMed label)
Label sectionWhat it says
Pharmacodynamics (12.2)"Semaglutide causes a delay of early postprandial gastric emptying"
Most common side effects, 5% or more (6.1)Nausea, vomiting, diarrhea, abdominal pain, constipation
Severe GI reactions (5.7)Not recommended in people with severe gastroparesis (warning revised October 2025)
Postmarketing reports (6.2)Ileus; intestinal obstruction; severe constipation, including fecal impaction
Pulmonary aspiration (5.10)Rare reports under general anesthesia or deep sedation

Source: Ozempic prescribing information on DailyMed [1].

How much does it slow it?

In one scan study, 37% of a solid meal was still in the stomach four hours after eating on semaglutide, versus 0% on placebo. Half the meal took 171 minutes to empty on semaglutide and 118 minutes on placebo [4].

That trial was small and specific: 20 women with polycystic ovary syndrome and obesity, over 12 weeks. The trial used the 1 mg weekly dose, and measured emptying with scintigraphy, a scan that tracks a lightly radioactive meal [4].

Gastric emptying on semaglutide vs placebo after 12 weeks (Jensterle 2023, solid meal)
Time after the mealExtra food retained on semaglutide (change from baseline)
1 hour+3.5%
2 hours+25.5%
3 hours+38.0%
4 hours+30.0% (37% of the meal still in the stomach, vs 0% on placebo)
Time to half-empty171 minutes, vs 118 on placebo

20 women with PCOS and obesity, randomized to semaglutide or placebo [4].

Share of a solid meal still in the stomach at 4 hours, %
Semaglutide
37%[4]
Placebo
0%[4]

Can Ozempic "paralyze" your digestive system?

Bowel stalling has been reported; its frequency cannot be estimated from these reports. The label lists ileus, a stalled bowel, among postmarketing reports, along with intestinal obstruction and severe constipation [1]. Postmarketing reports come from people using the drug after approval. They show something happened, not how often it happens or that the drug caused it.

The label also says Ozempic isn't recommended for people who already have severe gastroparesis, a condition where the stomach empties very slowly [1]. A 2026 review of published case reports found 13 people who developed gastroparesis on a GLP-1 drug, most often semaglutide. In those reports, symptoms cleared after the drug was stopped [8]. Thirteen cases can't tell you the risk. They describe a possible drug-associated problem and symptom resolution in those reported people, without proving causality or universal reversibility.

Does the slowdown last?

It may fade for some people, but the evidence is mixed and depends on how it's measured.

  • Reviews of the drug class say long-acting GLP-1 drugs slow the stomach less over time, an effect called tachyphylaxis [6].
  • A 20-week trial of the 2.4 mg dose, using an indirect blood test, found no evidence of delayed emptying by week 20 [5]. The Ozempic label notes a similar result at that dose [1]. That trial was run and largely written by Novo Nordisk, which makes semaglutide.
  • The 12-week scan study still found a marked delay, using the more direct scan method [4].
  • A 2026 study of fasted surgery patients found solid food in the stomach in 42% of people on semaglutide, versus 7% of matched people not on it [7].

So some tests suggest the effect fades, and others suggest food can still linger, even after fasting. If you notice fullness easing after the first weeks, that fits the class pattern. It doesn't mean the effect is gone.

Digestion and surgery or sedation

Because food can stay in the stomach longer, the label warns about rare cases of pulmonary aspiration, where stomach contents reach the lungs, during general anesthesia or deep sedation. It adds that the available data aren't enough to set rules for reducing that risk [1].

Other questions people ask about Ozempic and their body, including inflammation, are in does semaglutide help with inflammation.

When to call your prescriber

Severe or persistent stomach pain, repeated vomiting, being unable to pass stool or gas, or bloating that won't settle needs prompt medical attention.

The label backs this up. It warns of severe GI reactions [1]. It also warns about pancreatitis, which can show up as persistent, severe stomach pain that sometimes spreads to the back, and about gallbladder problems [1]. Those aren't digestion slowing down, but they can feel similar, which is why lasting pain is worth a call rather than a wait.

Milder fullness, nausea or constipation is common, especially early on. Even so, it's your prescriber's call what, if anything, to change. Slower emptying is how the medicine works, so persistent symptoms need assessment rather than an assumption about their cause.

Do Wegovy and semaglutide slow digestion too? Yes

Wegovy is the same molecule, semaglutide, and its label says plainly: "Semaglutide delays gastric emptying" [2]. The slowdown is a property of semaglutide itself, although the size and duration of the effect vary with formulation, dose and how it is measured; compounded products were not the products in these trials. Zepbound's label says tirzepatide delays gastric emptying too, with the delay largest after the first dose and easing over time [3].

The brands are labeled for different things. Ozempic is for type 2 diabetes: to improve blood sugar, to lower the risk of major heart events in people with heart disease, and to lower kidney risks in people with chronic kidney disease [1]. Wegovy is for long-term weight reduction, for lowering the risk of major heart events in adults with heart disease and obesity or overweight, and for a type of fatty liver disease with scarring [2].

If you're weighing how semaglutide affects your body beyond the gut, see building muscle on Ozempic and does Wegovy give you energy. For the bigger picture on metabolic goals, the metabolic health shortlist is the place to start.

Providers that offer Semaglutide

  • CoreAge RxPartner

    People comparing GLP-1 plans who want the chosen rate and renewal terms confirmed before paying.

    Visit site →
  • DirectMedsPartner

    People who will obtain the exact product, renewal schedule and pharmacy assignment before paying.

    Visit site →
  • EmbodyPartner

    People who can confirm the full bundle and accept limited voluntary refund rights.

    Visit site →

Compare more providers →

Frequently asked

How long does Ozempic delay gastric emptying?
In one scan study, half of a solid meal took about 171 minutes to leave the stomach on semaglutide, versus 118 on placebo. Effects vary by person and may ease over time.
Does Ozempic cause gastroparesis?
The label says it isn't recommended for people who already have severe gastroparesis, and rare bowel problems such as ileus have been reported. Report severe or lasting symptoms to your prescriber.
How do you speed up digestion on Ozempic?
Slower stomach emptying is how the medicine works, and persistent symptoms deserve assessment. Bothersome symptoms are for your prescriber to assess.
Is Ozempic approved for weight loss?
No. Ozempic is approved for type 2 diabetes. Wegovy is the semaglutide brand labeled for weight management.
Does Wegovy slow digestion?
Yes. Wegovy is semaglutide, the same medicine as Ozempic, and its label says semaglutide delays gastric emptying.
Does semaglutide delay gastric emptying?
Yes. Its labels say it delays stomach emptying after meals, and a scan study found food stayed in the stomach markedly longer than on placebo.

Sources

  1. [1] Ozempic (semaglutide) injection, prescribing information (DailyMed, 2026) (2026). DailyMed label
  2. [2] Wegovy (semaglutide) prescribing information (DailyMed, 2026) (2026). DailyMed label
  3. [3] Zepbound (tirzepatide) injection, prescribing information (revised August 2026) (2026). DailyMed label
  4. [4] Jensterle M. Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity (2023). PMID 36511825
  5. [5] Friedrichsen M. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity (2021). PMID 33269530
  6. [6] Nauck MA. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art (2021). PMID 33068776
  7. [7] Vlaeminck N. Gastric ultrasound in patients receiving semaglutide: a prospective, multicentre, matched control study (2026). PMID 41631344
  8. [8] Olubodun T. Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes (2026). PMID 42594084

Related research